Wyeth Pharmaceuticals, a division of Wyeth , announced the appointment of Andreas Krebs, 50, to president – Europe/Middle East/Africa and Canada, effective immediately. In this new role, Krebs will report to Joseph M. Mahady, president – Wyeth Pharmaceuticals, and senior vice president, Wyeth.
Krebs joined the company in July 2003 as general manager, Wyeth Germany, and since that time has worked to transform the German affiliate into one of the fastest growing companies in the market. He serves on the board of the VFA (Germany's trade organization for research companies) and is a member of the board of trustees in the Max Planck Institute for Molecular Biomedicine and the Paul Ehrlich Society for Chemotherapy.
Prior to joining Wyeth, Krebs was with Bayer for approximately 20 years, where he held a variety of pharmaceutical marketing and sales leadership positions in Europe, Latin America, Asia and Canada. He holds a degree in Commercial Management and Business Administration from the In-House Academy of Woelm Pharma, Eschwege, Germany.